본문 바로가기
KERD
논문KCI 등재

Screening strategy for non-alcoholic fatty liver disease

Wai-Kay Seto|Man-Fung Yuen|Lung-Yi Mak|Saisai Zhang
대한간학회 (The korean Association for the Study of the Liver)|2023.04|Clinical and Molecular Hepatology|제29권 제2호|pp. 103-122

6

조회

0

다운로드

4

인용

0

참고문헌

키워드

Diabetes mellitusFibrosisFatty liverNAFLDMetabolic diseases

초록

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, affecting approximately 25% of the general population worldwide, and is forecasted to increase global health burden in the 21st century. With the advancement of non-invasive tests for assessing and monitoring of steatosis and fibrosis, NAFLD screening is now feasible, and is increasingly highlighted in international guidelines related to hepatology, endocrinology, and pediatrics. Identifying high-risk populations (e.g., diabetes mellitus, obesity, metabolic syndrome) based on risk factors and metabolic characteristics for non-invasive screening is crucial and may aid in designing screening strategies to be more precise and effective. Many screening modalities are currently available, from serum-based methods to ultrasonography, transient elastography, and magnetic resonance imaging, although the diagnostic performance, cost, and accessibility of different methods may impact the actual implementation. A two-step assessment with serum-based fibrosis-4 index followed by imaging test vibration-controlled transient elastography can be an option to stratify the risk of liver-related complications in NAFLD. There is a need for fibrosis surveillance, as well as investigating the cost-effectiveness of different screening algorithms and engaging primary care for first-stage triage screening.

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, affecting approximately 25% of the general population worldwide, and is forecasted to increase global health burden in the 21st century. With the advancement of non-invasive tests for assessing and monitoring of steatosis and fibrosis, NAFLD screening is now feasible, and is increasingly highlighted in international guidelines related to hepatology, endocrinology, and pediatrics. Identifying high-risk populations (e.g., diabetes mellitus, obesity, metabolic syndrome) based on risk factors and metabolic characteristics for non-invasive screening is crucial and may aid in designing screening strategies to be more precise and effective. Many screening modalities are currently available, from serum-based methods to ultrasonography, transient elastography, and magnetic resonance imaging, although the diagnostic performance, cost, and accessibility of different methods may impact the actual implementation. A two-step assessment with serum-based fibrosis-4 index followed by imaging test vibration-controlled transient elastography can be an option to stratify the risk of liver-related complications in NAFLD. There is a need for fibrosis surveillance, as well as investigating the cost-effectiveness of different screening algorithms and engaging primary care for first-stage triage screening.

참고문헌 (139)

  1. Younossi ZM, "Global epidemiology of nonalcoholic fatty liver diseaseMeta-analytic assessment of prevalence, incidence, and outcomes", Hepatology, 64, pp.73~84 (2016)
  2. Singh S, "Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis : a systematic review and meta-analysis of paired-biopsy studies", Clin Gastroenterol Hepatol, 13, pp.643~654 (2015)
  3. Brunt EM, "Pathology of nonalcoholic fatty liver disease", Nat Rev Gastroenterol Hepatol, 7, pp.195~203 (2010)
  4. Goldberg D, "Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation", Gastroenterology, 152, pp.1090~1099 (2017)
  5. Simon TG, "Mortality in biopsy-confirmed nonalcoholic fatty liver disease : results from a nationwide cohort", Gut, 70, pp.1375~1382 (2021)
  6. Taylor RS, "Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease : a systematic review and meta-analysis", Gastroenterology, 158, pp.1611~1625 (2020)
  7. Hagström H, "Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD", J Hepatol, 67, pp.1265~1273 (2017)
  8. Wijarnpreecha Karn, "Evaluation and Management of Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease", Clinical and Molecular Hepatology, 27(2), pp.221~235 (2021), 대한간학회[DOI]
  9. Estes C, "Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030", J Hepatol, 69, pp.896~904 (2018)
  10. Neilson LJ, "Implementation of a care bundle improves the management of patients with non-alcoholic fatty liver disease", Frontline Gastroenterol, 12, pp.578~585 (2021)
  11. Chalasani N, "The diagnosis and management of non-alcoholic fatty liver disease : practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association", Hepatology, 55, pp.2005~2023 (2012)
  12. European Association for the Study of the Liver(EASL), "EASL-EASDEASO clinical practice guidelines for the management of nonalcoholic fatty liver disease", J Hepatol, 64, pp.1388~1402 (2016)
  13. Chalasani N, "The diagnosis and management of nonalcoholic fatty liver disease : practice guidance from the American Association for the Study of Liver Diseases", Hepatology, 67, pp.328~357 (2018)
  14. Eslam M, "The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease", Hepatol Int, 14, pp.889~919 (2020)
  15. 강성희, "KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease", Clinical and Molecular Hepatology, 27(3), pp.363~401 (2021), 대한간학회
  16. McPherson S, "Quality standards for the management of non-alcoholic fatty liver disease(NAFLD) : consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group", Lancet Gastroenterol Hepatol, 7, pp.755~769 (2022)
  17. Vos MB, "NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children : recommendations from the Expert Committee on NAFLD(ECON)and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition(NASPGHAN)", J Pediatr Gastroenterol Nutr, 64, pp.319~334 (2017)
  18. Estrada E, "Children’s Hospital Association consensus statements for comorbidities of childhood obesity", Child Obes, 10, pp.304~317 (2014)
  19. Barlow SE, "Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report", Pediatrics, 120(Suppl 4), pp.S164~S192 (2007)
  20. American Diabetes Association, "4. Comprehensive medical evaluation and assessment of comorbidities : standards of medical care in diabetes-2019", Diabetes Care, 42(Suppl 1), pp.S34~S45 (2019)
  21. Sagan A, "Screening:when is it appropriate and how can we get it right?", European Observatory on Health Systems and Policies, ~ (2020)
  22. Smith BW, "Nonalcoholic fatty liver disease and diabetes mellitus : pathogenesis and treatment", Nat Rev Endocrinol, 7, pp.456~465 (2011)
  23. Buzzetti E, "The multiple-hit pathogenesis of non-alcoholic fatty liver disease(NAFLD)", Metabolism, 65, pp.1038~1048 (2016)
  24. Targher G, "Clinical review : nonalcoholic fatty liver disease : a novel cardiometabolic risk factor for type 2 diabetes and its complications", J Clin Endocrinol Metab, 98, pp.483~495 (2013)
  25. Tomah S, "Nonalcoholic fatty liver disease and type 2 diabetes : where do diabetologists stand?", Clin Diabetes Endocrinol, 6, pp.9~ (2020)
  26. Kotronen A, "Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects", Diabetes Care, 31, pp.165~169 (2008)
  27. Wong VW, "Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese : a population study using proton-magnetic resonance spectroscopy and transient elastography", Gut, 61, pp.409~415 (2012)
  28. Kwok R, "Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements : a prospective cohort study", Gut, 65, pp.1359~1368 (2016)
  29. Doycheva I, "Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE", Aliment Pharmacol Ther, 43, pp.83~95 (2016)
  30. Bedogni G, "Prevalence of and risk factors for nonalcoholic fatty liver disease : the Dionysos nutrition and liver study", Hepatology, 42, pp.44~52 (2005)
  31. Frith J, "Potential strategies to improve uptake of exercise interventions in non-alcoholic fatty liver disease", J Hepatol, 52, pp.112~116 (2010)
  32. Aron-Wisnewsky J, "Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese", J Hepatol, 56, pp.225~233 (2012)
  33. Sasaki A, "Bariatric surgery and non-alcoholic Fatty liver disease: current and potential future treatments", Front Endocrinol(Lausanne), 5, pp.164~ (2014)
  34. Subichin M, "Liver disease in the morbidly obese : a review of 1000 consecutive patients undergoing weight loss surgery", Surg Obes Relat Dis, 11, pp.137~141 (2015)
  35. Machado M, "Hepatic histology in obese patients undergoing bariatric surgery", J Hepatol, 45, pp.600~606 (2006)
  36. Naveau S, "The diagnostic accuracy of transient elastography for the diagnosis of liver fibrosis in bariatric surgery candidates with suspected NAFLD", Obes Surg, 24, pp.1693~1701 (2014)
  37. Wong VW, "Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease", Am J Gastroenterol, 107, pp.1862~1871 (2012)
  38. Gaggini M, "Non-alcoholic fatty liver disease(NAFLD)and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease", Nutrients, 5, pp.1544~1560 (2013)
  39. Gómez-Ambrosi J, "Body mass index classification misses subjects with increased cardiometabolic risk factors related to elevated adiposity", Int J Obes(Lond), 36, pp.286~294 (2012)
  40. Younossi ZM, "Nonalcoholic fatty liver disease in lean individuals in the United States", Medicine(Baltimore), 91, pp.319~327 (2012)
  41. Kojima S, "Increase in the prevalence of fatty liver in Japan over the past 12 years : analysis of clinical background", J Gastroenterol, 38, pp.954~961 (2003)
  42. Das K, "Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease", Hepatology, 51, pp.1593~1602 (2010)
  43. Younes R, "Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean : time for reappraisal of BMI-driven approach?", Gut, 71, pp.382~390 (2022)
  44. Lonardo A, "Nonalcoholic fatty liver disease : evolving paradigms", World J Gastroenterol, 23, pp.6571~6592 (2017)
  45. Eren F, "Accuracy of Fibrosis-4 index and nonalcoholic fatty liver disease fibrosis scores in metabolic(dysfunction)associated fatty liver disease according to body mass index : failure in the prediction of advanced fibrosis in lean and morbidly obese individuals", Eur J Gastroenterol Hepatol, 34, pp.98~103 (2022)
  46. Zou B, "Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999-2016", J Intern Med, 288, pp.139~151 (2020)
  47. Ye Q, "Global prevalence, incidence, and outcomes of non-obese or lean nonalcoholic fatty liver disease : a systematic review and metaanalysis", Lancet Gastroenterol Hepatol, 5, pp.739~752 (2020)
  48. Cornier MA, "The metabolic syndrome", Endocr Rev, 29, pp.777~822 (2008)
  49. Ballestri S, "Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis", J Gastroenterol Hepatol, 31, pp.936~944 (2016)
  50. Zhang T, "Metabolic syndrome and its components as predictors of nonalcoholic fatty liver disease in a northern urban Han Chinese population : a prospective cohort study", Atherosclerosis, 240, pp.144~148 (2015)
  51. Yamamura S, "Profiles of advanced hepatic fibrosis evaluated by FIB-4 index and shear wave elastography in health checkup examinees", Hepatol Res, 50, pp.199~213 (2020)
  52. Yuan J, "Fatty liver disease caused by high-alcohol-producing Klebsiella pneumoniae", Cell Metab, 30, pp.675~688 (2019)
  53. Eslam M, "MAFLD : a consensus-driven proposed nomenclature for metabolic associated fatty liver disease", Gastroenterology, 158, pp.1999~2014 (2020)
  54. Eslam M, "A new definition for metabolic dysfunction-associated fatty liver disease : an international expert consensus statement", J Hepatol, 73, pp.202~209 (2020)
  55. Mak LY, "Letter regarding"A new definition for metabolic dysfunction-associated fatty liver disease : An international expert consensus statement"", J Hepatol, 73, pp.1573~1574 (2020)
  56. Boyle M, "The bidirectional impacts of alcohol consumption and the metabolic syndrome : cofactors for progressive fatty liver disease", J Hepatol, 68, pp.251~267 (2018)
  57. Hung SC, "Prevalence and related factors of non-alcoholic fatty liver disease among the elderly in Taiwan", Eur Geriatr Med, 4, pp.78~81 (2013)
  58. Goh SC, "Prevalence and risk factors of nonalcoholic fatty liver disease in a multiracial suburban Asian population in Malaysia", Hepatol Int, 7, pp.548~554 (2013)
  59. DiStefano JK, "NAFLD and NASH in postmenopausal women : implications for diagnosis and treatment", Endocrinology, 161, pp.bqaa134~ (2020)
  60. Golabi P, "Prevalence and outcomes of non-alcoholic fatty liver disease(NAFLD)among Asian American adults in the United States", Liver Int, 39, pp.748~757 (2019)
  61. Le MH, "Ethnic influence on nonalcoholic fatty liver disease prevalence and lack of disease awareness in the United States, 2011-2016", J Intern Med, 287, pp.711~722 (2020)
  62. Riley MR, "Underdiagnosis of pediatric obesity and underscreening for fatty liver disease and metabolic syndrome by pediatricians and pediatric subspecialists", J Pediatr, 147, pp.839~842 (2005)
  63. Patton HM, "Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis", Gastroenterology, 135, pp.1961~1971 (2008)
  64. Eslam M, "Genetics and epigenetics of NAFLD and NASH : clinical impact", J Hepatol, 68, pp.268~279 (2018)
  65. Dongiovanni P, "PNPLA3 I148M polymorphism and progressive liver disease", World J Gastroenterol, 19, pp.6969~6978 (2013)
  66. Sookoian S, "Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3gene(PNPLA3)on the susceptibility and histological severity of nonalcoholic fatty liver disease", Hepatology, 53, pp.1883~1894 (2011)
  67. Valenti L, "Homozygosity for the patatin-like phospholipase-3", adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease, 2010, pp.51, 1209~1217
  68. Liu YL, "TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease", Nat Commun, 5, pp.4309~ (2014)
  69. Dongiovanni P, "Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease", Hepatology, 61, pp.506~514 (2015)
  70. Loomba R, "Heritability of hepatic fibrosis and steatosis based on a prospective twin study", Gastroenterology, 149, pp.1784~1793 (2015)
  71. Stender S, "Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci", Nat Genet, 49, pp.842~847 (2017)
  72. Caussy C, "Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis", J Clin Invest, 127, pp.2697~2704 (2017)
  73. Dulai PS, "Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease : Systematic review and meta-analysis", Hepatology, 65, pp.1557~1565 (2017)
  74. Armstrong MJ, "Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort", J Hepatol, 56, pp.234~240 (2012)
  75. Vali Y, "Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD:A systematic review and meta-analysis", J Hepatol, 73, pp.252~262 (2020)
  76. Srivastava A, "Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease", J Hepatol, 71, pp.371~378 (2019)
  77. Tokushige K, "Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease", nonalcoholic steatohepatitis 2020, 2021, pp.56, 951~963
  78. Gunn NT, "The use of liver biopsy in nonalcoholic fatty liver disease : when to biopsy and in whom", Clin Liver Dis, 22, pp.109~119 (2018)
  79. Kleiner DE, "Design and validation of a histological scoring system for nonalcoholic fatty liver disease", Hepatology, 41, pp.1313~1321 (2005)
  80. Brunt EM, "Nonalcoholic fatty liver disease(NAFLD)activity score and the histopathologic diagnosis in NAFLD : distinct clinicopathologic meanings", Hepatology, 53, pp.810~820 (2011)
  81. Gwyneth Soon, "Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective", Clinical and Molecular Hepatology, 27(1), pp.44~57 (2021), 대한간학회[DOI]
  82. Neuberger J, "Guidelines on the use of liver biopsy in clinical practice from the British Society of Gastroenterology, the Royal College of Radiologists and the Royal College of Pathology", Gut, 69, pp.1382~1403 (2020)
  83. Poynard T, "Biomarkers as a first-line estimate of injury in chronic liver diseases : time for a moratorium on liver biopsy?", Gastroenterology, 128, pp.1146~1148 (2005)
  84. Sebastiani G, "Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy", World J Gastroenterol, 12, pp.3682~3694 (2006)
  85. Bedogni G, "The Fatty Liver Index : a simple and accurate predictor of hepatic steatosis in the general population", BMC Gastroenterol, 6, pp.33~ (2006)
  86. Lee JH, "Hepatic steatosis index : a simple screening tool reflecting nonalcoholic fatty liver disease", Dig Liver Dis, 42, pp.503~508 (2010)
  87. Munteanu M, "Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference", Aliment Pharmacol Ther, 44, pp.877~889 (2016)
  88. Wong VW, "Noninvasive biomarkers in NAFLD and NASH-current progress and future promise", Nat Rev Gastroenterol Hepatol, 15, pp.461~478 (2018)
  89. Wong GL, "Noninvasive algorithm of enhanced liver fibrosis and liver stiffness measurement with transient elastography for advanced liver fibrosis in chronic hepatitis B", Aliment Pharmacol Ther, 39, pp.197~208 (2014)
  90. Guha IN, "Noninvasive markers of fibrosis in nonalcoholic fatty liver disease : validating the European Liver Fibrosis Panel and exploring simple markers", Hepatology, 47, pp.455~460 (2008)
  91. Nobili V, "Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease", Gastroenterology, 136, pp.160~167 (2009)
  92. Imbert-Bismut F, "Biochemical markers of liver fibrosis in patients with hepatitis C virus infection : a prospective study", Lancet, 357, pp.1069~1075 (2001)
  93. Munteanu M, "Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease", Aliment Pharmacol Ther, 48, pp.1117~1127 (2018)
  94. Shaheen AA, "Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis : a systematic review", Hepatology, 46, pp.912~921 (2007)
  95. Angulo P, "Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease", Gastroenterology, 145, pp.782~789 (2013)
  96. Angulo P, "The NAFLD fibrosis score : a noninvasive system that identifies liver fibrosis in patients with NAFLD", Hepatology, 45, pp.846~854 (2007)
  97. Wong VW, "Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis", Am J Gastroenterol, 103, pp.1682~1688 (2008)
  98. Wong VW, "Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1 : definition, risk factors and assessment", J Gastroenterol Hepatol, 33, pp.70~85 (2018)
  99. Hannah WN Jr, "Noninvasive imaging methods to determine severity of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis", Hepatology, 64, pp.2234~2243 (2016)
  100. Hernaez R, "Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver : a meta-analysis", Hepatology, 54, pp.1082~1090 (2011)
  101. Dasarathy S, "Validity of real time ultrasound in the diagnosis of hepatic steatosis : a prospective study", J Hepatol, 51, pp.1061~1067 (2009)
  102. Cengiz M, "Sonographic assessment of fatty liver : intraobserver and interobserver variability", Int J Clin Exp Med, 7, pp.5453~5460 (2014)
  103. Afdhal NH, "Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C : a United States multicenter study", Clin Gastroenterol Hepatol, 13, pp.772~779 (2015)
  104. Asrani SK, "Incorporation of noninvasive measures of liver fibrosis into clinical practice : diagnosis and prognosis", Clin Gastroenterol Hepatol, 13, pp.2190~2204 (2015)
  105. Sasso M, "Controlled attenuation parameter(CAP) : a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis : preliminary study and validation in a cohort of patients with chronic liver disease from various causes", Ultrasound Med Biol, 36, pp.1825~1835 (2010)
  106. Karlas T, "Individual patient data meta-analysis of controlled attenuation parameter(CAP)technology for assessing steatosis", J Hepatol, 66, pp.1022~1030 (2017)
  107. Seto WK, "Association between hepatic steatosis, measured by controlled attenuation parameter, and fibrosis burden in chronic hepatitis B", Clin Gastroenterol Hepatol, 16, pp.575~583 (2018)
  108. Papatheodoridi M, "Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease", J Hepatol, 74, pp.1109~1116 (2021)
  109. Mózes FE, "Diagnostic accuracy of noninvasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis", Gut, 71, pp.1006~1019 (2022)
  110. Park CC, "Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease", Gastroenterology, 152, pp.598~607 (2017)
  111. European Association for Study of Liver, "EASL-ALEH Clinical Practice Guidelines : Non-invasive tests for evaluation of liver disease severity and prognosis", J Hepatol, 63, pp.237~264 (2015)
  112. Bohte AE, "The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy : a meta-analysis", Eur Radiol, 21, pp.87~97 (2011)
  113. Venkatesh SK, "Magnetic resonance elastography of liver : technique, analysis, and clinical applications", J Magn Reson Imaging, 37, pp.544~555 (2013)
  114. Dulai PS, "MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH : Clinical trials to clinical practice", J Hepatol, 65, pp.1006~1016 (2016)
  115. Singh S, "Diagnostic performance of magnetic resonance elastography in staging liver fibrosis : a systematic review and metaanalysis of individual participant data", Clin Gastroenterol Hepatol, 13, pp.440~451 (2015)
  116. Imajo K, "Magnetic Resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography", Gastroenterology, 150, pp.626~637 (2016)
  117. Cassinotto C, "Liver stiffness in nonalcoholic fatty liver disease : A comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy", Hepatology, 63, pp.1817~1827 (2016)
  118. Cassinotto C, "Non-invasive assessment of liver fibrosis with impulse elastography : comparison of Supersonic Shear Imaging with ARFI and FibroScan®", J Hepatol, 61, pp.550~557 (2014)
  119. Angelini G, "Accurate liquid biopsy for the diagnosis of non-alcoholic steatohepatitis and liver fibrosis", Gut (2022)[DOI]
  120. Lee CH, "Circulating thrombospondin-2 as a novel fibrosis biomarker of nonalcoholic fatty liver disease in type 2 diabetes", Diabetes Care, 44, pp.2089~2097 (2021)
  121. Gang Xu, "Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis", Clinical and Molecular Hepatology, 27(2), pp.329~345 (2021), 대한간학회[DOI]
  122. Touboul A, "Unmixing multi-spectral electrical impedance tomography(EIT)predicts clinical-standard controlled attenuation parameter(CAP)for nonalcoholic fatty liver disease classification : a feasibility study", Annu Int Conf IEEE Eng Med Biol Soc, 2022, pp.576~579 (2022)
  123. Gaggini M, "Altered amino acid concentrations in NAFLD : Impact of obesity and insulin resistance", Hepatology, 67, pp.145~158 (2018)
  124. Hwi Young Kim, "Recent advances in nonalcoholic fatty liver disease metabolomics", Clinical and Molecular Hepatology, 27(4), pp.553~559 (2021), 대한간학회[DOI]
  125. Nimer N, "Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression", Metabolism, 116, pp.154457~ (2021)
  126. Loomba R, "Gut microbiome-based metagenomic signature for noninvasive detection of advanced fibrosis in human nonalcoholic fatty liver disease", Cell Metab, 25, pp.1054~1062 (2017)
  127. Molina-Molina E, "(13C)-Methacetin breath test provides evidence of subclinical liver dysfunction linked to fat storage but not lifestyle", JHEP Rep, 3, pp.100203~ (2020)
  128. Fierbinteanu-Braticevici C, "The role of ¹³C-methacetin breath test for the non-invasive evaluation of nonalcoholic fatty liver disease", J Gastrointestin Liver Dis, 22, pp.149~156 (2013)
  129. Braden B, "13C-methacetin breath test as liver function test in patients with chronic hepatitis C virus infection", Aliment Pharmacol Ther, 21, pp.179~185 (2005)
  130. Vilar-Gomez E, "Non-invasive assessment of nonalcoholic fatty liver disease : Clinical prediction rules and blood-based biomarkers", J Hepatol, 68, pp.305~315 (2018)
  131. Boursier J, "New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD", J Hepatol, 71, pp.389~396 (2019)
  132. Petta S, "Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD", Aliment Pharmacol Ther, 46, pp.617~627 (2017)
  133. Maya-Miles D, "Management of NAFLD patients with advanced fibrosis", Liver Int, 41(Suppl 1), pp.95~104 (2021)
  134. Serra-Burriel M, "Transient elastography for screening of liver fibrosis:cost-effectiveness analysis from six prospective cohorts in Europe and Asia", J Hepatol, 71, pp.1141~1151 (2019)
  135. Srivastava A, "Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease", BMC Gastroenterol, 19, pp.122~ (2019)
  136. Corey KE, "Screening for nonalcoholic steatohepatitis in individuals with type 2 diabetes : a cost-effectiveness analysis", Dig Dis Sci, 61, pp.2108~2117 (2016)
  137. Noureddin M, "Screening for nonalcoholic fatty liver disease in persons with type 2 diabetes in the United States is cost-effective : a comprehensive cost-utility analysis", Gastroenterology, 159, pp.1985~1987 (2020)
  138. Vilar-Gomez E, "Cost effectiveness of different strategies for detecting cirrhosis in patients with nonalcoholic fatty liver disease based on United States health care system", Clin Gastroenterol Hepatol, 18, pp.2305~2314 (2020)
  139. Ng CH, "Living in the non-alcoholic fatty liver disease silent epidemic : a qualitative systematic review of patients’ perspectives", Aliment Pharmacol Ther, 56, pp.570~579 (2022)

관련 논문AI추천

Identification of high-risk subjects in nonalcoholic fatty liver diseaseChristiane Stern, Laurent Castera대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제1호Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver diseaseGrace Lai-Hung Wong, Jimmy Che-To Lai, Sherlot Juan Song, Terry Cheuk-Fung Yip, Vincent Wai-Sun Wong, Yichong Jiang, Yue Wang대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제2호Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and futureAsako Nogami, Atsushi Nakajima, Kento Imajo, Masato Yoneda, Michihiro Iwaki, Satoru Saito, Takashi Kobayashi, Yasushi Honda, Yuji Ogawa대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제2호Screening strategies for non-alcoholic fatty liver disease: a holistic approach is neededHans-Michael Steffen, Münevver Demir, Philipp Kasper대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제2호Application of transient elastography in nonalcoholic fatty liver diseaseGrace Lai-Hung Wong, Vincent Wai-Sun Wong, Xinrong Zhang대한간학회 · Clinical and Molecular Hepatology2020 · 제26권 제2호Recent Epidemiology of Nonalcoholic Fatty Liver DiseaseAhmed Aijaz, Kim Donghee, Murag Soumya거트앤리버 소화기연관학회협의회 · Gut and Liver2021 · 제15권 제2호

이 간행물의 다른 논문 (53건)

Congratulatory remarksSi Hyun Baepp. 1-1Special thanksSeung Up Kimpp. 4-4MAFLD: How is it different from NAFLD?Ming-Hua Zheng, Jacob George, Cameron Gofton, Yadhavan Upendranpp. 17-31Global incidence and prevalence of nonalcoholic fatty liver diseaseEunice Tan, Mark D. Muthiah, Cheng Han Ng, Margaret LP Teng, Kai En Chan, Darren JH Tan, Wen Hui Lim, Ju Dong Yang, Daniel Q. Huangpp. 32-42Nonalcoholic fatty liver disease and non-liver comorbiditiesRichie Manikat, Mindie H. Nguyenpp. 86-102
원문 보기